Compare TGE & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGE | EQ |
|---|---|---|
| Founded | 2023 | 2017 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.3M | 64.5M |
| IPO Year | N/A | 2018 |
| Metric | TGE | EQ |
|---|---|---|
| Price | $1.25 | $1.97 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.50 |
| AVG Volume (30 Days) | 43.6K | ★ 563.4K |
| Earning Date | 04-20-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.99 | ★ N/A |
| Revenue Growth | N/A | ★ 13.89 |
| 52 Week Low | $0.78 | $0.29 |
| 52 Week High | $12.99 | $2.70 |
| Indicator | TGE | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 44.29 | 51.03 |
| Support Level | $1.01 | $1.22 |
| Resistance Level | $1.62 | $1.97 |
| Average True Range (ATR) | 0.09 | 0.23 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 35.84 | 27.05 |
The Generation Essentials Group is a media and entertainment company. Its publications L'Officiel and The Art Newspaper publish print editions in a total of nearly 28 countries and territories and digital contents. It operate in the movie production sector having produced various Asia-focused movies. It operate in three operating segments: media and entertainment segment, hotel operations, hospitality and VIP services segment and strategic investment segment. Key revenue is generated from strategic investment segment that is engage in proprietary investments and management of portfolio, including listed and unlisted equity shares investments and movie income right investments.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.